Trials / Completed
CompletedNCT00567047
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-01-01
- First posted
- 2007-12-04
- Last updated
- 2009-03-25
Locations
6 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00567047. Inclusion in this directory is not an endorsement.